Vasoactive Intestinal Peptide Powder

Vasoactive Intestinal Peptide Powder (VIP) is a 28-amino acid, C-terminal aminated polypeptide belonging to the secretin/glucagon family. Endogenous VIP is widely distributed in the central and peripheral regions, especially in the intestine, respiratory tract, blood vessels, islets, immune system and the suprachiasmatic nucleus (SCN) of the hypothalamus.

With the progress of scientific research in the polypeptide market, the demand for polypeptide raw materials is increasing. Shaanxi Medibridge is an integrated industrial and trade manufacturer of polypeptide raw materials with over 14 years of industry experience, specializing in the purification of high-purity polypeptides. We can provide polypeptides with a purity of up to 99.988%, while the usual standard is ≥95%.

Our advantages

1. High purity meets the standards.

2. Batch variations are strictly controlled.

3. Standardize the freeze-drying process to maintain stability.

4. Support diverse customization.

5. Respond quickly to demands.

6. Adhere to industry standards and regulatory requirements to ensure compliance.

VIP mediates signal transduction through Class B GPCR receptors VPAC1/VPAC2, is mainly coupled with Gs, rapidly increases cAMP, and activates the PKA-CREB and EPAC-RAP1 axes. In some cells, the Gq/PLC/ IP3-Ca2 + branch and the β -Arrestin-mediated ERK pathway can be observed. The above-mentioned pathways not only regulate transient ion flux and effector protein activity, but also reshape gene transcription (such as Per, Fos, IL-10 promoters, etc.). After receptor activation, GRK - β -Arrestin desensitization and endocytosis occur. The distribution and density of receptor subtypes determine the amplitude and duration of the response.

In vascular and airway smooth muscle, cAMP/PKA inhibits L-type Ca2+ channels and MLCK activity, opens K+ channels such as BKCa/KATP, and promotes eNOS to produce NO on the endothelium. In synergy with the cGMP pathway, it generates significant vascular and bronchial dilation effects. In the epithelium and glands, PKA phosphorylates the CFTR and SLC26 transporters, enhancing the excretion of Cl−/HCO3−, and water is transferred along the osmotic gradient, explaining the increased exocrine of the pancreas and the watery diarrhea caused by VIPoma. In the islets of the pancreas, Vasoactive Intestinal Peptide Powder interacts with the glucose status and receptor subtypes, presenting an overall secretion pattern of "high glucose promoting insulin and low glucose promoting pancreatic hypertrophy".

In the neuroendocrinal-immune aspect, VIP is the core rhythm signal of the suprachiasmatic nucleus, mainly driven by VPAC2-camp-CREB to express Per1/Per2, synchronize neuronal oscillations and complete phase resets, and affect the circadian hormone rhythms of the HPA axis and peripheral tissues.

In the immune system, VIP inhibits NF - κB and p38 through PKA/EPAC, induces dendritic cell tolerance (↓CD80/86, ↓ IL-12), down-regulates TNF - α/ IL-6, up-regulates IL-10, promotes Treg and Th2 bias, and drives M2-like phenotypes in macrophages (↓iNOS, ↑Arg1). At the glial and neuronal levels, VIP exhibits anti-apoptotic and neurotrophic effects, involving the regulation of the PI3K/Akt and Bcl-2 families, and can modulate pain transmission.

1. How is the dosage determined?

It can take effect at the nM level, often starting from 0.1 to 100 nM, and is usually sufficient to raise the cAMP of the VPAC pathway.

First, conduct a small-scale gradient and time window pre-experiment, and then fine-tune it based on the receptor expression level of your cell line.

2. Which readings should be looked at? (How to determine if it is working

a. Second Messenger: Has cAMP risen? Is PKA/CREB phosphorylated? The EPAC indicator can serve as collateral evidence.

b. Smooth muscle/Blood vessels: Perform in vitro loop segment tension tests, combined with calcium imaging; Meanwhile, measure the release of nitric oxide (NO).

c. Immune cells: Detect cytokines (TNF - α/ IL-6 / IL-10), and in combination with phenotypic markers, observe the changes in the NF - κB/STAT pathway.

d. Circadian Rhythm: Use the Per reporting system of SCN slices or neurons to draw the phase response curve.

3. How to prove that the result was caused by "it"? (Rather than going off course

a. Receptor antagonists, or receptor silencing;

b. Set heat-inactivated peptides and random sequence peptides as negative controls;

c. Conduct parallel comparisons with peptides of the same family (PACAP, secretin) to eliminate non-specific stimuli.

4. Reduce material loss due to "sticking to the wall"

Peptides are easily adsorbed by the tube wall, so low-protein adsorption consumables should be preferred.

b. 0.1% BSA or a small amount of Tween - 20 (0.01-0.05%) can be added to the working solution. Choose the best of the two and try it with your own system before making a decision.

Shaanxi Medibridge manufactures peptides for universities and research labs worldwide. We supply lyophilized vasoactive intestinal peptide powder for research use only, with guaranteed purity ≥99.72% and a complete COA (HPLC/LCMS) plus full batch traceability. Count on dependable lead times, protective packaging, rapid technical support, steady instock supply, and global shipping. For quotes or samples, contact hi@medibridgeapi.com or WhatsApp +44 07548632075.

Hot Tags: vasoactive intestinal peptide powder, China vasoactive intestinal peptide powder manufacturers, suppliers, factory, Cagrilintide Powder, Dsip Peptide Powder, Foxo4 Peptide, Glutathione Powder, Pt 141 Peptide Powder, Tesamorelin Powder